Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

01 December 2007

Therapeutic Drug Monitoring of tacrolimus in renal transplant patients

B. Solnica, K. Słowińska-Solnica, E. Ignacak, J. W. Naskalski

Ann Transplant 2008; 13(1): 39-40 :: ID: 880202


Background: The aim of this study was the retrospective evaluation of the relationship between the dosage of tacrolimus and its blood concentrations in renal transplant patients and assessment of the relationship between blood drug levels and the pharmacological effect.
Material/Methods: The studied group consisted of 64 patients (42 men and 22 women) on combined immunosuppressive treatment using tacrolimus (T), prednisolone (P), mycophenolate (M), azthioprine (A) and sirolimus (S) in various combinations including tacrolimus. The tacrolimus doses ranged from 0.05 to 0.3 mg/kg/day. During the 32-42 weeks follow-up whole blood tacrolimus levels were measured with microparticle enzyme immunoassay on IMx analyzer.
Results: No significant correlation between tacrolimus doses and its blood concentrations was found. Drug levels were within the subtherapeutic range in 89.1% of patients during the entire follow-up. In remaining patients 75-92.3% of results were also subtherapeutic, less than 25% of results were in the therapeutic range, no toxic levels were obtained. The graft rejection was observed in 10.9% patients, men only, 6 on T-P-M treatment (15.8% of T-P-M group) and one on T-P-A treatment. Acute tubular necrosis was observed in
21.9% of patients, 9 men (8 on T-P-M and 1 on T-P-A treatment) and 5 women (2 on T-P-M, 2 on T-P-A and 1 on T-P treatment). All graft rejections and ATN episodes occurred with sub-therapeutic tacrolimus concentrations. Conclusions: No significant dose-concentrations relationship indicates the need for individualized, empiric dosage and therapeutic monitoring of tacrolimus. In majority of studied patients the combined immunosupressive treatment including tacrolimus in subtherapeutic blood levels was effective. Thus, separate therapeutic ranges should be established for combined treatment and for both sexes. On the other hand subtherapeutic drug levels were found in all patients with graft rejection. However, these rejection episodes can not be explained solely by sub-therapeutic tacrolimus concentrations.

Keywords: Tacrolimus, mycophenolate, Cytocheratin 7


Most Viewed Current Articles

26 Jan 2022 : Review article  

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models

DOI :10.12659/AOT.934924

Ann Transplant 2022; 27:e934924

24 Aug 2021 : Review article  

Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives

DOI :10.12659/AOT.931664

Ann Transplant 2021; 26:e931664

29 Dec 2021 : Original article  

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358